iNova Pharmaceuticals - Nyal Ibuprofen 200mg

Therapeutic Goods Act 1989

Approval under section 42DF for use of restricted representations by iNova Pharmaceuticals (Australia) Pty Ltd

I, Elizabeth Butt, as a delegate of the Secretary to the Department of Health, on receipt of an application from iNova Pharmaceuticals (Australia) Pty Ltd have approved under section 42DF of the Therapeutic Goods Act 1989 (the Act) the restricted representations described in paragraph (A) below for use in consumer advertising of the product identified in paragraph (B):

1. Representations to the effect that NYAL IBUPROFEN 200mg can be used for the temporary relief of pain and/or inflammation associated with arthritis, osteoarthritis, rheumatic pain, fibrositis and neuralgia (where referenced individually or collectively)
2. NYAL IBUPROFEN, ibuprofen 200mg tablet blister pack (AUST R 351890)

Dated this 21st day of June 2021

Signed electronically

Elizabeth Butt
Delegate of the Secretary to the Department of Health
Advertising and Compliance Education and Policy Section
Regulatory Compliance Branch